GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » PS Ratio

Vaccinex (Vaccinex) PS Ratio : 2.33 (As of May. 17, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Vaccinex PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vaccinex's share price is $5.5366. Vaccinex's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.37. Hence, Vaccinex's PS Ratio for today is 2.33.

The historical rank and industry rank for Vaccinex's PS Ratio or its related term are showing as below:

VCNX' s PS Ratio Range Over the Past 10 Years
Min: 2.05   Med: 87.41   Max: 1966.99
Current: 2.37

During the past 8 years, Vaccinex's highest PS Ratio was 1966.99. The lowest was 2.05. And the median was 87.41.

VCNX's PS Ratio is ranked better than
82.7% of 1000 companies
in the Biotechnology industry
Industry Median: 9.125 vs VCNX: 2.37

Vaccinex's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.37.

Warning Sign:

Vaccinex Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Vaccinex was -9.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 29.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -41.70% per year.

During the past 8 years, Vaccinex's highest 3-Year average Revenue per Share Growth Rate was 29.80% per year. The lowest was -45.90% per year. And the median was -37.60% per year.

Back to Basics: PS Ratio


Vaccinex PS Ratio Historical Data

The historical data trend for Vaccinex's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex PS Ratio Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial 118.79 773.49 33.25 99.45 7.58

Vaccinex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.45 23.34 20.80 4.64 7.58

Competitive Comparison of Vaccinex's PS Ratio

For the Biotechnology subindustry, Vaccinex's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaccinex's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's PS Ratio distribution charts can be found below:

* The bar in red indicates where Vaccinex's PS Ratio falls into.



Vaccinex PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Vaccinex's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=5.5366/2.373
=2.33

Vaccinex's Share Price of today is $5.5366.
Vaccinex's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Vaccinex  (NAS:VCNX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Vaccinex PS Ratio Related Terms

Thank you for viewing the detailed overview of Vaccinex's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaccinex (Vaccinex) Business Description

Traded in Other Exchanges
N/A
Address
1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Executives
Van Strydonck, Gerald E. director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer director, 10 percent owner, officer: President and CEO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Albert Friedberg director, 10 percent owner
Jacob B. Frieberg director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans officer: Chief Operating Officer C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala officer: Chief Commercial Officer 1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk director 1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc. director 1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater director C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard officer: SVP, Development 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith officer: SVP, Research & CSO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins officer: SVP & Chief Operating Officer 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620